大麻与烟草使用及COVID-19结局
该回顾性队列研究利用美国中西部一家大型学术医疗中心2020年2月1日至2022年1月31日的电子健康记录,纳入72 501例COVID-19患者,评估当前大麻使用和烟草吸烟与住院、ICU入住及全因死亡的关系。多变量模型校正后,当前烟草吸烟与住院(OR 1.72;95%CI 1.62-1.82;P<.001)、ICU入住(OR 1.22;95%CI 1.10-1.34;P<.001)和全因死亡(OR 1.37;95%CI 1.20-1.57;P<.001)风险升高显著相关。大麻使用与住院(OR 1.80;95%CI 1.68-1.93;P<.001)和ICU入住(OR 1.27;95%CI 1.14-1.41;P<.001)风险升高显著相关,但与全因死亡无关(OR 0.97;95%CI 0.82-1.14;P=.69)。作者认为大麻使用可能是COVID-19相关并发症的独立危险因素。
要点
- 当前烟草吸烟与COVID-19住院风险升高相关(OR 1.72;95%CI 1.62-1.82;P<.001)。
- 当前烟草吸烟与COVID-19 ICU入住风险升高相关(OR 1.22;95%CI 1.10-1.34;P<.001)。
- 当前烟草吸烟与COVID-19全因死亡风险升高相关(OR 1.37;95%CI 1.20-1.57;P<.001)。
- 大麻使用与COVID-19住院风险升高相关(OR 1.80;95%CI 1.68-1.93;P<.001),校正了烟草吸烟、疫苗接种、合并症、诊断日期和人口学因素。
- 大麻使用与COVID-19 ICU入住风险升高相关(OR 1.27;95%CI 1.14-1.41;P<.001),但与全因死亡无关(OR 0.97;95%CI 0.82-1.14;P=.69)。
适用人群与场景
- 2020年2月1日至2022年1月31日在美国中西部一家大型学术医疗中心至少1次就诊中被识别为COVID-19的患者,共72 501例;平均(SD)年龄48.9(19.3)岁;43 315例(59.7%)为女性。
- 当前吸烟9710例(13.4%);既往吸烟17 654例(24.4%);当前大麻使用7060例(9.7%)。
研究设计与关键结果
- 研究类型为回顾性队列研究,使用电子健康记录数据,纳入72 501例COVID-19患者。
- 暴露为医疗记录中记载的当前大麻使用和烟草吸烟;主要结局为COVID-19感染后住院、ICU入住和全因死亡,采用多变量模型评估关联。
- 当前烟草吸烟与住院风险升高显著相关(OR 1.72;95%CI 1.62-1.82;P<.001),与ICU入住风险升高显著相关(OR 1.22;95%CI 1.10-1.34;P<.001),与全因死亡风险升高显著相关(OR 1.37;95%CI 1.20-1.57;P<.001)。
- 大麻使用与住院风险升高显著相关(OR 1.80;95%CI 1.68-1.93;P<.001),与ICU入住风险升高显著相关(OR 1.27;95%CI 1.14-1.41;P<.001),与全因死亡无显著关联(OR 0.97;95%CI 0.82-1.14;P=.69);该分析校正了烟草吸烟、疫苗接种、合并症、诊断日期和人口学因素。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,大麻使用可能是COVID-19相关并发症的独立危险因素,即使考虑了吸烟、疫苗接种状态、合并症和其他危险因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.
OBJECTIVE: To examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.
EXPOSURES: Current cannabis use and tobacco smoking, as documented in the medical encounter.
MAIN OUTCOMES AND MEASURES: Health outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.
RESULTS: A total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19-related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.
参考来源
- Griffith NB, Baker TB, Heiden BT, et al. Cannabis, Tobacco Use, and COVID-19 Outcomes. JAMA Netw Open. 2024. PMID: 38904961. doi:10.1001/jamanetworkopen.2024.17977
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。